Papulonodular mucinosis: a systematic review on clinicopathologic characteristics, course and treatment options

Si-Yu Luo1, Qin-Xiao Wang1, Kai-Yi Zhou1

  • 1Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Insights

Papulonodular mucinosis (PNM), a rare lupus erythematosus variant, presents with skin lesions and dermal mucin. Treatment with hydroxychloroquine and glucocorticoids often leads to remission.

Area of Science:

  • Dermatology
  • Rheumatology
  • Pathology

Background:

  • Papulonodular mucinosis (PNM) is a rare cutaneous mucinosis and a variant of lupus erythematosus.
  • Limited large-scale studies exist on its clinicopathological features and treatment efficacy.

Purpose of the Study:

  • To review existing literature on PNM.
  • To identify clinical and histological features.
  • To evaluate treatment outcomes.

Main Methods:

  • Systematic literature review of PubMed, Embase, and Cochrane Library databases up to March 1, 2024.
  • Inclusion of 37 studies comprising 44 patients.

Main Results:

  • PNM lesions manifest as generalized papules, plaques, and nodules with abundant dermal mucin deposition.
  • The relationship between PNM and systemic lupus erythematosus (SLE) is variable; PNM does not appear to increase SLE organ involvement or activity.
  • Diagnosis requires a combination of clinical, historical, and histopathological findings, though misdiagnosis is possible before lupus erythematosus (LE) is evident.

Conclusions:

  • Accurate diagnosis of PNM relies on integrated clinical and histopathological assessment.
  • Hydroxychloroquine and systemic glucocorticoids are primary treatments, yielding partial or complete remission in most cases.